Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 1;2:16003. doi: 10.1038/cddiscovery.2016.3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Cell Death Differentiation Association

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Downregulation of selected IRES targets is regulated by caspase-3 except for c-Myc, which is regulated by K-Ras inhibition. (a–c) Caspase-3 inhibition restores the expression of selected IRES targets but fails to protect c-Myc and N-Myc. Caspase-3 inhibitor z-DEVD-fmk restored Myc isoforms in TNF-α+AZ58-treated cells at (a) 8 h but failed to restore c-Myc and N-Myc at (b) 24 h. Bar graphs in panel (a) indicate that the DNA fragmentation was prevented by z-DEVD-fmk in all conditions (n=3). The simplified schematic diagram in panel (c) explains the action of z-DEVD-fmk on p70S6K and IRES targets. (d) Caspase-3 inhibition prevents secondary necrosis in blebbishields generated by TNF-α+AZ58 (arrows, secondary necrosis). (e) MW shift (oligomers) of K-Ras with FasL+AZ58 differs in quantity from MW shift with TNF-α+AZ58 or TRAIL+AZ58. (f) K-Ras activation assay. GST-Raf1-RBD binding to K-Ras was abolished by AZ58 combinations with TNF-α, FasL, and TRAIL.